Oncology research is uncovering a wealth of new therapeutic targets that hold promise for combating cancer. From novel signaling pathways implicated in tumor growth and metastasis to components of the tumor microenvironment that promote immune evasion and treatment resistance, researchers are identifying a diverse array of targets for drug development.
Small molecule inhibitors, monoclonal antibodies, and immune-based therapies are being designed to specifically target these vulnerabilities in cancer cells, with the goal of halting tumor progression and improving patient outcomes.
